[HTML][HTML] Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance

I Kapoor, J Bodo, BT Hill, ED Hsi, A Almasan - Cell death & disease, 2020 - nature.com
Defects in apoptosis can promote tumorigenesis and impair responses of malignant B cells
to chemotherapeutics. Members of the B-cell leukemia/lymphoma-2 (BCL-2) family of …

The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee

E Campo, ES Jaffe, JR Cook… - Blood, The Journal …, 2022 - ashpublications.org
Since the publication of the Revised European-American Classification of Lymphoid
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …

Plasma cell myeloma and related neoplasms

RB Lorsbach, ED Hsi, A Dogan… - American journal of …, 2011 - academic.oup.com
Session 1 of the 2009 Workshop of the Society for Hematopathology/European Association
of Haematopathology, Cleveland, OH, focused on plasma cell neoplasms. This report …

T-lymphoblastic leukemia/lymphoma

MJ You, LJ Medeiros, ED Hsi - American journal of clinical …, 2015 - academic.oup.com
Objectives To review important concepts from the 2013 Society for Hematopathology/
European Association for Haematopathology Workshop session on T-acute lymphoblastic …

[PDF][PDF] Genetic and functional drivers of diffuse large B cell lymphoma

A Reddy, J Zhang, NS Davis, AB Moffitt, CL Love… - Cell, 2017 - cell.com
Diffuse large B cell lymphoma (DLBCL) is the most common form of blood cancer and is
characterized by a striking degree of genetic and clinical heterogeneity. This heterogeneity …

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene …

S Hu, ZY Xu-Monette, A Tzankov… - Blood, The Journal …, 2013 - ashpublications.org
Diffuse large B-cell lymphoma (DLBCL) is stratified into prognostically favorable germinal
center B-cell (GCB)–like and unfavorable activated B-cell (ABC)–like subtypes based on …

CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma

ED Hsi, R Steinle, B Balasa, S Szmania… - Clinical Cancer …, 2008 - AACR
Purpose: We generated a humanized antibody, HuLuc63, which specifically targets CS1
(CCND3 subset 1, CRACC, and SLAMF7), a cell surface glycoprotein not previously …

The genetic landscape of mutations in Burkitt lymphoma

C Love, Z Sun, D Jima, G Li, J Zhang, R Miles… - Nature …, 2012 - nature.com
Burkitt lymphoma is characterized by deregulation of MYC, but the contribution of other
genetic mutations to the disease is largely unknown. Here, we describe the first completely …

Genetic heterogeneity of diffuse large B-cell lymphoma

J Zhang, V Grubor, CL Love… - Proceedings of the …, 2013 - National Acad Sciences
Diffuse large B-cell lymphoma (DLBCL) is the most common form of lymphoma in adults.
The disease exhibits a striking heterogeneity in gene expression profiles and clinical …

[HTML][HTML] Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)

JL Rubenstein, ED Hsi, JL Johnson… - Journal of Clinical …, 2013 - ncbi.nlm.nih.gov
Purpose Concerns regarding neurocognitive toxicity of whole-brain radiotherapy (WBRT)
have motivated development of alternative, dose-intensive chemotherapeutic strategies as …